CLEC12A and acute myeloid leukemia: Potential targets for the treatment of AML include CD33, CD45, CD96, CD123, CD135, C-type lectin-like molecule-1 (CLL1), and FLT3 and so on, among of which CD33 and CD123 also expressed on hematopoietic stem cells (HSCs) while CLL1 absent on megakaryocytic progenitor cells and CD34+/CD38-HSCs (13).